Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing next-generation biotherapeutics for immune-mediated diseases. It delivers treatments through its platform, ATTOBODY. The company was founded by Tao Fu, Zaneta Odrowaz, and Petter Veiby on December 16, 2022 and is headquartered in San Carlos, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Attovia Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Attovia Therapeutics Inc. market cap is $785.22M.
What is the 52-week high for Attovia Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Attovia Therapeutics Inc. 52 week high is $22.79 as of August 07, 2026.
What is the 52-week low for Attovia Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Attovia Therapeutics Inc. 52 week low is $17.00 as of August 07, 2026.
What is Attovia Therapeutics Inc. stock price today?
Attovia Therapeutics Inc. stock price today is $20.38.
What was Attovia Therapeutics Inc. stock price yesterday?
Attovia Therapeutics Inc. stock price yesterday was $21.90.
What is the Price-to-Book ratio of Attovia Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Attovia Therapeutics Inc. P/B ratio is -6.9867.
What is the 50-day moving average of Attovia Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Attovia Therapeutics Inc. 50-day moving average is $19.76.